MDxHealth SA filings document a foreign private issuer focused on precision diagnostics for prostate cancer and other urologic diseases. The company’s Form 6-K reports furnish financial results, interim reports, press releases, governance updates and materials incorporated by reference into registration statements.
The filing record includes shareholder meeting notices, proxy and attendance materials, a share option plan, authorized-capital reports, warrant terms and acquisition-related disclosures. MDXH filings also document the completed Exosome Diagnostics acquisition through audited financial statements and pro forma financial information, along with amendments to earnout obligations related to the GPS acquisition.
MDxHealth SA Chief Financial Officer Ron Kalfus reported his existing holdings of share options over ordinary shares. The positions span multiple grants from 2019 to 2025, with strikes set in Euros and U.S. dollars and expirations running from 2029 through 2035.
They include options over 75,000 ordinary shares at an exercise price of $2.62 expiring on June 22, 2034, and 100,000 shares at $1.47 expiring on April 11, 2035. Earlier grants at prices such as 12.40, 8.00, 13.75, 6.84 and 2.90 Euros generally vest in three equal annual installments or upon achieving specified performance criteria evaluated by the Board of Directors.
MDxHealth SA director Don M. Hardison reported initial holdings of company share options. He holds options to purchase 30,000 ordinary shares at $2.62 per share, granted on June 22, 2024 and vested in full at the following annual general shareholders' meeting, and options for 10,000 ordinary shares at $2.18 per share, granted on June 27, 2025 and vesting in full at the next annual general shareholders' meeting.
MDxHealth SA director Sanford Jay Siegel filed an initial ownership report showing compensation-related options, not a market trade. He holds options to purchase 10,000 ordinary shares at $2.18 per share, granted on June 27, 2025, vesting in full at the next-year annual general shareholders' meeting and expiring on June 27, 2035.
MDxHealth SA director Hilde Windels has filed an initial ownership report showing indirect holdings of share options in MDxHealth SA through Hilde Windels BV. The positions include options over 1,000 ordinary shares at €49.70 expiring on June 1, 2028 and 1,000 shares at €12.80 expiring on July 1, 2029. Additional grants cover 30,000 ordinary shares at $2.62 expiring on June 22, 2034 and 10,000 shares at $2.18 expiring on June 27, 2035. These options were granted in prior years and vest or vested in connection with annual general shareholders' meetings, and the reporting person disclaims beneficial ownership of securities held by Hilde Windels BV except to the extent of any pecuniary interest.
MDxHealth SA director Koen Hoffman filed an initial statement of beneficial ownership, detailing his existing share option holdings. He reports options over 1,000 and 2,000 ordinary shares at exercise prices of 49.70 Euros and 12.80 Euros, granted in 2018 and 2019 and already fully vested. He also reports options over 30,000 and 10,000 ordinary shares at exercise prices of $2.62 and $2.18, granted in 2024 and 2025. Part of these options are held indirectly through Ahok BV, where he owns 53.33%, and he disclaims beneficial ownership beyond his pecuniary interest.
MDxHealth presents an annual report highlighting continued losses, going concern uncertainty and reliance on key prostate cancer tests. As of December 31, 2025, the company had an accumulated deficit of $403.0 million, a 2025 net loss of $33.5 million and net cash outflows from operations of $2.2 million. Management expects further losses and notes that failure to raise capital could jeopardize its ability to continue as a going concern. A $100 million senior secured credit facility with OrbiMed, maturing in 2029, imposes revenue and liquidity covenants and is secured by substantially all assets. Revenue is concentrated in Confirm mdx and GPS mdx tests, which generated about 76% of 2025 revenue and depend heavily on Medicare and commercial reimbursement. The report also describes intense competition in molecular diagnostics, complex billing and reimbursement risk, extensive regulatory exposure, and the importance of MDxHealth’s patent portfolio and CLIA-certified laboratories.
MDxHealth SA director Michael Holder reports initial holdings of share options. The filing shows options to purchase 10,000 ordinary shares at an exercise price of $2.18 per share, granted on June 27, 2025. These options vest in full at the annual general shareholders' meeting held in the calendar year after the grant year and expire on June 27, 2035.
MVM Partners, LLC has filed an initial ownership report for MDxHealth SA, showing indirect holdings of 4,700,457 Ordinary Shares. These shares are held by private investment funds managed by MVM Partners. MVM states that it may be deemed a beneficial owner through its role as investment manager but disclaims beneficial ownership beyond any pecuniary interest.
MDxHealth reported strong growth for the year ended December 31, 2025, with revenue up 20% to $107.9 million and fourth-quarter revenue up 19% to $29.5 million. Growth was driven mainly by its urology-focused precision diagnostic tests, with tissue-based tests providing most of sales.
Full-year gross profit rose 26% to $69.6 million, and gross margin improved to 64.5% from 61.2%, helped by better fixed-cost absorption. Operating expenses increased 5% to $84.0 million, reflecting acquisition-related costs and higher headcount tied to the ExoDx business.
The company reduced its operating loss to $14.4 million from $24.7 million, and net loss narrowed 12% to $33.5 million. Adjusted EBITDA improved sharply to a loss of $1.1 million from a loss of $14.7 million, indicating progress toward profitability. Cash and cash equivalents were $29.0 million at year-end.
For 2026, MDxHealth guides revenue to $137–140 million, implying 27–30% growth, and aims to reach an adjusted EBITDA margin of 10% exiting 2026.